Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 10 | 2015 | 765 | 1.710 |
Why?
|
| DNA Repair | 7 | 2018 | 64 | 1.480 |
Why?
|
| BRCA1 Protein | 4 | 2018 | 10 | 1.240 |
Why?
|
| DNA Damage | 5 | 2015 | 99 | 0.660 |
Why?
|
| Stathmin | 3 | 2007 | 3 | 0.620 |
Why?
|
| Mutation | 5 | 2018 | 489 | 0.600 |
Why?
|
| Genes, BRCA1 | 3 | 2012 | 9 | 0.570 |
Why?
|
| Antineoplastic Agents | 3 | 2012 | 608 | 0.560 |
Why?
|
| Vinblastine | 3 | 2007 | 6 | 0.560 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 55 | 0.500 |
Why?
|
| Paclitaxel | 2 | 2007 | 67 | 0.490 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2007 | 37 | 0.490 |
Why?
|
| Small Molecule Libraries | 1 | 2014 | 11 | 0.480 |
Why?
|
| Cisplatin | 2 | 2011 | 76 | 0.470 |
Why?
|
| Deoxycytidine | 2 | 2011 | 68 | 0.470 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2011 | 29 | 0.470 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 261 | 0.450 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 726 | 0.430 |
Why?
|
| Hydrazines | 1 | 2012 | 4 | 0.410 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2018 | 82 | 0.370 |
Why?
|
| Gene Silencing | 2 | 2007 | 48 | 0.340 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 10 | 0.330 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 10 | 0.280 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 104 | 0.270 |
Why?
|
| Microtubule Proteins | 1 | 2002 | 1 | 0.220 |
Why?
|
| DNA Glycosylases | 2 | 2015 | 3 | 0.210 |
Why?
|
| Phosphoproteins | 1 | 2002 | 49 | 0.210 |
Why?
|
| Female | 9 | 2015 | 20015 | 0.180 |
Why?
|
| Mice | 3 | 2012 | 2484 | 0.180 |
Why?
|
| Humans | 11 | 2018 | 32114 | 0.160 |
Why?
|
| Ligases | 1 | 2015 | 5 | 0.130 |
Why?
|
| Endonucleases | 1 | 2015 | 4 | 0.130 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2015 | 15 | 0.130 |
Why?
|
| Microtubules | 2 | 2007 | 23 | 0.120 |
Why?
|
| Animals | 3 | 2012 | 7542 | 0.120 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 18 | 0.120 |
Why?
|
| Cell Cycle | 2 | 2006 | 77 | 0.120 |
Why?
|
| Lovastatin | 1 | 2013 | 7 | 0.120 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 15 | 0.110 |
Why?
|
| Receptor, erbB-2 | 1 | 2012 | 65 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 157 | 0.100 |
Why?
|
| Mammary Glands, Animal | 1 | 2011 | 65 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2011 | 141 | 0.090 |
Why?
|
| Cell Survival | 2 | 2010 | 285 | 0.090 |
Why?
|
| Apoptosis | 2 | 2010 | 360 | 0.080 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 268 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 40 | 0.070 |
Why?
|
| Cell Division | 1 | 2007 | 99 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2007 | 58 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2007 | 75 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 55 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2006 | 17 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2007 | 229 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2002 | 289 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2006 | 604 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 458 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 171 | 0.050 |
Why?
|
| Transfection | 1 | 2002 | 191 | 0.050 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 17 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2018 | 84 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2018 | 193 | 0.040 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2013 | 4 | 0.030 |
Why?
|
| Deoxyguanosine | 1 | 2013 | 4 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2013 | 33 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 25 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 53 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 238 | 0.030 |
Why?
|
| Lipids | 1 | 2013 | 232 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2013 | 231 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2013 | 225 | 0.020 |
Why?
|
| Rad51 Recombinase | 1 | 2010 | 3 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 19 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 66 | 0.020 |
Why?
|
| Histones | 1 | 2010 | 53 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 835 | 0.020 |
Why?
|
| Adult | 2 | 2013 | 9380 | 0.020 |
Why?
|
| Middle Aged | 2 | 2013 | 11839 | 0.020 |
Why?
|
| Neutropenia | 1 | 2002 | 29 | 0.010 |
Why?
|
| Vomiting | 1 | 2002 | 24 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2002 | 35 | 0.010 |
Why?
|
| Nausea | 1 | 2002 | 53 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2002 | 56 | 0.010 |
Why?
|
| Anemia | 1 | 2002 | 58 | 0.010 |
Why?
|
| Fever | 1 | 2002 | 61 | 0.010 |
Why?
|
| Fatigue | 1 | 2002 | 85 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2002 | 82 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2002 | 447 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 538 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2002 | 548 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2002 | 3306 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 3990 | 0.010 |
Why?
|
| Aged | 1 | 2002 | 10314 | 0.000 |
Why?
|